A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy
Status: | Recruiting |
---|---|
Conditions: | Dermatology |
Therapuetic Areas: | Dermatology / Plastic Surgery |
Healthy: | No |
Age Range: | 19 - Any |
Updated: | 4/21/2016 |
Start Date: | February 2015 |
End Date: | March 2016 |
Contact: | Isabella C Guiha |
Email: | IGuiha@CLDerm.com |
Phone: | 858 657 1004 |
A Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy
A double-blind, placebo controlled study conducted at a single study site. Evaluating the
role of systemic antihistamine therapy in the reduction of adverse effects associated with
topical 5-aminolevulinic acid photodynamic therapy.
role of systemic antihistamine therapy in the reduction of adverse effects associated with
topical 5-aminolevulinic acid photodynamic therapy.
Inclusion Criteria:
- Age > 18
- Subjects with 5-20 actinic keratosis of the face
- Patients undergoing photodynamic therapy (PDT) to the face for AK with
5-aminolevulinic acid (ALA) activated by blue light.
- Must be willing to give and sign a HIPPA form, photo consent and informed consent
form.
- Must be willing to comply with study dosing and complete the entire course of the
study.
- Female patients will be either of non-childbearing potential defined as:
1. Having no uterus
2. No menses for at least 12 months.
Or;
(WOCBP) women of childbearing potential must agree to use an effective method of birth
control during the course of the study, such as:
1. Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device
2. Intrauterine coil
3. Bilateral tubal ligation
4. Barrier method used with an additional form of contraception (e.g., sponge,
spermicide or condom)
5. Abstinence (If practicing abstinence must agree to use barrier method described above
(d) if becomes sexually active).
6. Vasectomized partner g. Negative urine pregnancy test results Baseline prior to study
entry (if applicable)
Exclusion Criteria:
- Presence of incompletely healed wound in treatment area
- Presence of known or suspected BCC or SCC in treatment area
- Previous PDT or treatment of the face with any topical cytotoxic or immunomodulatory
agent for AKs within the past 6 months
- Co-existing potentially confounding skin condition within treatment area (e.g.
eczema, psoriasis, XP, rosacea) at investigator's discretion
- Presence of tattoo and/or scar in the treatment area that in the investigators
opinion would interfere with study assessments
- Subjects with known photosensitivity or taking photosensitizing medications listed
below:
1. Oral diabetes medicines
2. Griseofulvin
3. Thiazide diuretics
4. Sulfonylureas
5. Phenothiazines
6. Tetracycline's
7. St. John's Wort
- Use of oral/topical retinoids within 1 month of Baseline
- Subjects with a history of sensitivity to porphyrins
- Subjects with recently excessive exposure of the treatment area to sunlight or
artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing) or
expectations of tanning during the time of the study
- Female subjects who are pregnant, nursing an infant or planning a pregnancy during
the study [throughout the course of the study
- Presence or evidence of any conditions that in the opinion of the investigator might
impede the subject's ability to give consent or comply with protocol requirements.
- Current participation or participation within 30 days prior to the start of this
study in a drug or other investigational research study
- History of non-compliance with clinical research protocols
- Ablative laser resurfacing to on their face within 12 months
- Non-ablative laser or light procedures to their face within the past 3 months
- Microdermabrasion (light or medium skin peel) treatment on their face within the past
30 days
We found this trial at
1
site
San Diego, California 92121
Principal Investigator: Mitchel P Goldman, MD
Phone: 858-657-1004
Click here to add this to my saved trials